IN8bio Inc. is a clinical-stage biotechnology company. It focuses on developing therapies for the treatment of cancers, including solid tumors using allogeneic, autologous, and genetically modified gamma-delta T cells. The company's principal candidate includes INB-200, which are in clinical stage. IN8bio Inc. is based in New York.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-19.44M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.64 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -91.18% |
| Return on Assets (Trailing 12 Months) | -76.93% |
| Current Ratio (Most Recent Fiscal Quarter) | 8.21 |
| Quick Ratio (Most Recent Fiscal Quarter) | 8.21 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.86 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.25 |
| Earnings per Share (Most Recent Fiscal Year) | $-4.44 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.62 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 9.86M |
| Free Float | 8.43M |
| Market Capitalization | $11.83M |
| Average Volume (Last 20 Days) | 0.08M |
| Beta (Past 60 Months) | 0.24 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 14.50% |
| Percentage Held By Institutions (Latest 13F Reports) | 92.05% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |